Skip to main content

As Expected, Solexa Closes $40M Private Stock Placement; Second of Two Tranches Worth $61M

NEW YORK, Jan. 20 (GenomeWeb News) - Solexa has closed a private stock placement valued at approximately $40 million, the company said today.

 

The transaction is the second and final closing of a $65-million private-equity financing round   with a group of institutional investors. In total, Solexa received approximately $61 million after deducting offering expenses.

 

Under terms of the second closing, Solexa sold about 6.1 million shares of common stock at $6.50 per share, and issued warrants to buy an additional 2.2 million shares at $7.50 per share.

 

The first closing, completed on Nov. 23, 2005, raised approximately $25 million from the sale of about 3.9 million shares of common stock and the issuance of about 1.3 million warrants.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.